GSK plc (LON:GSK)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 57.83B |
| Revenue (ttm) | 31.53B |
| Net Income (ttm) | 3.15B |
| Shares Out | 4.06B |
| EPS (ttm) | 0.76 |
| PE Ratio | 18.73 |
| Forward PE | 8.34 |
| Dividend | 0.61 (4.28%) |
| Ex-Dividend Date | May 15, 2025 |
| Volume | 6,000,152 |
| Average Volume | 8,146,027 |
| Open | 1,441.00 |
| Previous Close | 1,428.50 |
| Day's Range | 1,418.50 - 1,448.00 |
| 52-Week Range | 1,242.50 - 1,808.50 |
| Beta | 0.27 |
| RSI | 54.78 |
| Earnings Date | Apr 28, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
GSK shares break six-session winning streak
GSK wins EU backing for multiple myeloma drug, Blenrep
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult pat...
GSK wins FDA label expansion for asthma therapy Nucala in COPD
GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic lung disease commonly known as "smoker's lung", the company said on Thursda...
Pharma stocks rally: Glaxo surges 7%, Torrent gains after Q4; Gland steady post mixed results
Pharma stocks were trading firmly in the green on Tuesday morning, with GlaxoSmithKline Pharmaceuticals leading the charge—rising 7.4% to ₹2,992.80 as of 10:05 AM. The broader sector saw widespread bu...
GSK's Blood-Cancer Treatment Combinations Approved in Japan
The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.
Notable healthcare headlines for the week: UnitedHealth, Novo Nordisk and GSK in focus
The S&P 500 Health Care Index Sector (XLV) slipped 4.05% during the week.
iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating
iTeos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock here.
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion
GSK plc (NYSE: GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa . Under the agreement, GSK will pay up to $2 billion in total cash consideration. This include...
GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B
GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion
The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone payments of $800 million.
GSK to buy efimosfermin for up to $2 billion
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine from Boston Pharmaceuticals, for up to $2 billion.
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious...
FTSE 100 Live 14 May: GSK unveils $2bn acquisition, Imperial Brands posts results
GSK Pharma share price jumps 5% as Q4 EBITDA rises 29.5% YoY to Rs 333.2 crore
GSK Pharma’s shares surged 5% following the release of its Q4 FY25 financial results. The company’s consolidated revenue for the quarter increased by 4.8%, reaching Rs 974.4 crore compared to Rs 929.8...
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile
iTeos ends belrestotug program with GSK after Phase ... Full story available on Benzinga.com
ITeos, GSK discontinue lung cancer therapy development
iTeos Therapeutics and partner GSK said on Tuesday that they terminated the development of their experimental lung cancer therapy after its failure to significantly improve progression free survival i...
GSK, iTeos end lung cancer asset development after trial failure
India's GlaxoSmithKline Pharma reports profit rise on strong demand
India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs.
AstraZeneca and GSK in the firing line as Trump targets big pharma: ALEX BRUMMER
No one expected US peace in our time at the Geneva talks with China at the weekend, but what emerged is better than predicted.
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.
Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'
President plans to use executive powers, saying US should pay ‘same price as nation that pays the lowest price'